MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association

MannKind Corporation (NASDAQ:MNKD) is one of the Best American Penny Stocks to Buy According to AnalystsMannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

Dr. Michael J. Haller of the University of Florida presented key results from the INHALE-1 Phase 3 clinical trial. This trial tested Afrezza, the company’s inhaled insulin, in children and teens aged 4-17 with diabetes. The company highlighted several new studies at the meeting, including updates on inhaled insulin’s benefits for children and adults with both type 1 and type 2 diabetes. Moreover, two other presentations discussed patient experiences and compared Afrezza to placebo in adults with type 2 diabetes.

MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association

A close-up of a doctor’s hand pressing on an inhaler, conveying the effect of the company’s therapeutic products.

Looking ahead, MannKind Corporation (NASDAQ:MNKD) plans to release full pediatric safety and efficacy data in the second quarter of 2025. The company aims to apply to expand Afrezza’s use in children later in the year.

MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapies and delivery devices for serious endocrine and lung diseases.

While we acknowledge the potential of MNKD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNKD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.